The Tribble with APL: a new road to therapy

Carmody, R. and Keeshan, K. (2017) The Tribble with APL: a new road to therapy. Cancer Cell, 31(5), pp. 612-613. (doi:10.1016/j.ccell.2017.04.011) (PMID:28486101)

[img]
Preview
Text
140027.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

341kB

Abstract

The t(15;17) translocation generates a PML-RARα fusion protein causative for acute promyelocytic leukemia (APL). Li et al. now identify the pseudokinase stress protein TRIB3 as an important factor in APL disease progression and therapy resistance. Targeting the interaction of TRIB3 and PML-RARα using peptide technology provides a novel therapeutic approach.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Carmody, Dr Ruaidhri and Keeshan, Dr Karen
Authors: Carmody, R., and Keeshan, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Cancer Cell
Publisher:Elsevier
ISSN:1535-6108
ISSN (Online):1878-3686
Published Online:08 May 2017
Copyright Holders:Copyright © 2017 Elsevier Inc.
First Published:First published in Cancer Cell 31(5): 612-613
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record